Bivalent Antibody Format with Disulfide Bridge for Ophthalmic Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for age-related macular degeneration, such as VEGF inhibition, require frequent intravitreal injections and can cause systemic side effects due to high molecular weight drugs, which are not effectively retained in the eye and are rapidly cleared, leading to reduced efficacy and increased risk of systemic exposure.
Innovation Solution
A novel, low molecular weight, bivalent antibody format with improved stability and tissue penetration, specifically designed for ophthalmological applications, featuring an intra-chain disulfide bridge and a multimerization domain, allowing for reduced systemic exposure and prolonged intravitreal retention.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If full-length antibodies are used for VEGF inhibition, then therapeutic efficacy is achieved, but the frequency of injections must be high (every 4-6 weeks) due to rapid clearance from the eye
Solution Approach 1:
The patent modifies the molecular weight parameter of the antibody by creating truncated formats (e.g., removing Fc regions or using single-chain variants) to alter clearance kinetics. This parameter change enables prolonged intravitreal retention without sacrificing VEGF inhibition efficacy, thereby reducing injection frequency from every 4-6 weeks to potentially longer intervals.
2Reliability
If high dose application is used to maintain therapeutic levels, then efficacy is improved, but systemic drug exposure increases leading to side effects
Solution Approach 1:
The patent segments the full-length antibody into smaller functional units (e.g., Fab fragments, single-chain Fv variants) that retain antigen-binding capability but lack the Fc region responsible for systemic distribution and Fc-receptor interactions. This segmentation allows the drug to remain localized in the vitreous humor at effective concentrations without achieving high systemic exposure, thereby maintaining efficacy while reducing side effects.
3Loss of substance
If low molecular weight antibody formats are used, then systemic clearance is improved, but stability and structural integrity may be compromised
Solution Approach 1:
The patent creates composite antibody structures by combining antigen-binding domains (VH and VL) with stabilizing elements such as Fc fragments or engineered disulfide bridges. These composite formats maintain the low molecular weight necessary for rapid systemic clearance while incorporating structural features that enhance intravitreal stability and prevent premature degradation, thus achieving both improved clearance and enhanced stability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The novel antibody format enhances therapeutic efficacy by maintaining activity longer, reducing the frequency of injections, and minimizing systemic side effects while improving tissue penetration and stability, thus addressing the limitations of existing treatments for age-related macular degeneration.
Implementation Method 1
the introduction of an intra-chain disulfide bridge increases the stability of the novel bivalent antibody... the introduction of an intrachain disulfide bond between one of the antibody variable domains and the antibody constant domain resulted in an improvement of the structural stability of this new antibody
Implementation Method 2
One of the factors driving the clearance from drug from the eye is diffusion. The diffusive properties of a drug are mainly determined by the size of the drug
Data Source
Figure 1
Figure 2
AI summary
Herein is reported a recombinant fusion polypeptide comprising an antibody heavy chain variable domain, a multimerization domain and an antibody light chain variable domain, wherein the antibody heavy chain variable domain is fused (either directly or via a first (peptidic) linker) to one terminus of the multimerization domain, the antibody light chain variable domain is fused (either directly or via a second (peptidic) linker) to the respective other terminus of the multimerization domain, and the antibody heavy chain variable domain or the antibody light chain variable domain has a (intra-peptidic) disulphide bond to the multimerization domain.